June 2025 Updates - The Bioentrepreneurs: Stanford

CSO Dr. Sam Banister presented preclinical data on Xylo’s lead compound, XYL-1001, at the 5th Psychedelic Therapeutics & Drug Development Conference (San Diego), highlighting its potential as a non-hallucinogenic treatment for neuropsychiatric conditions.

Reconnected with the 2025 One Mind Accelerator, a program advancing innovation in mental health, and joined the Stanford Drug Discovery Symposium.

Featured on the Startup 360 and Human 3 podcasts discussing Xylo’s rebrand, U.S. expansion, and breakthrough approach to targeted neurotherapeutics.

Joined partners Tessara Therapeutics and the University of Sydney in Melbourne to advance a $6.2M CRC-P initiative developing next-gen treatments for substance use disorders.

Hiring: Currently recruiting a VP of R&D, Chief Development Officer and Clinical Advisory Board Member to help shape the next chapter of development.

Daniel Mokhtari, CEO and Co-founder, will be attending the 2025 BIO International Convention in Boston, and Velocity Bio is live on the BIO Partnering platform. They’d love to connect!

Kicked off Series A fundraising! − The proceeds will enable TwoStep to complete two value-inflection clinical trials for their targeted drug conjugate and radioligand therapy programs.

Will be attending the 2025 BIO International Convention in Boston and is now live on the BIO Partnering platform. They would love to connect!

Published Accuracy and Safety of a Continuous Noninvasive Blood Pressure Monitor in Neonates in Neonatology, a leading publication for fetal and neonatal research. The paper describes PyrAmes’ multi-site, pivotal clinical study for Boppli®, PyrAmes' groundbreaking blood pressure monitoring solution for infants under critical care. 

Starting with bladder cancer, achieved > 92% prognostic accuracy predicting disease recurrence—dramatically surpassing clinical standards—and uncovered novel therapeutic targets now entering validation.

Identified novel therapeutic targets in urologic cancers and are strategically exploiting them in disease-relevant model systems.

Recently expanded their AI/ML pipelines to integrate chromosomal instability signals with molecular network reconstruction, enabling deeper insights into disease mechanisms and the identification of actionable molecular drivers for clinical intervention —including degenerative disorders, proliferative diseases, cellular senescence, and genome instability syndromes.

Hiring: Senior Scientist in Target Discovery and Tissue Analysis

CEO, Natalise Kalea Robinson, will be speaking at Summit this month! If you will be attending and want to meet, reach out to [email protected].

Launched CUSTOM Health Discovery Kits. Want to test beyond your facial or scalp microbiome? Now, you can request a custom kit to test multiple areas across your body. Watch the video announcement.

Presented at Gitex Berlin and was honored in the AI innovation spotlight, representing the intersection of healthtech, AI, and microbiome science.

Strong Funding Milestone: secured over $23 million to date, underpinning Logomix’s ambitious expansion plans into US markets and further development of transformative cell therapies.

Strategic Collaborations with MIT and Emerging Biotechs: initiated high-impact research partnerships, including an innovative collaboration with Prof. Ron Weiss’s lab at MIT, focused on regenerative medicine and next-generation cell therapies. This work complements their strategic alliances with emerging biotech companies in the US.

AI-Driven Cell Engineering: launched early collaborations leveraging Logomix's engineered cell lines with a leading AI x Biotech company, integrating machine learning to predict and enhance therapeutic outcomes. Actively exploring further AI partnerships to drive innovation at the intersection of AI and regenerative medicine.

ISSCR 2025 Oral Presentation: Yas, their scientific lead, was selected to deliver an oral presentation at the ISSCR Annual Meeting (June 2025), highlighting breakthroughs from Logomix's genome editing platform and its applications in stem cell therapies.

Expanding Leadership Team: welcomed Dr. Ramy Ibrahim (former Chief Medical Officer at the Parker Institute for Cancer Immunotherapy) and Dr. Mitchell Finer (co-founder and former President of R&D at ElevateBio) as senior scientific advisors. Their deep expertise in genome editing, iPSC-derived therapies, and clinical translation will help guide Logomix’s strategy as they advance their Geno-Writing™ platform toward transformative, off-the-shelf cell therapies.

Completed preliminary accuracy studies that shows 2x accuracy compared to existing systems on the market in end-to-end placement. This was achieved after a thorough re-design of optical and instrument calibration.

Dr. James Hu, MD, presented Skylight, the company’s platform for surgical access, at the 13th Annual Global Spine Congress in Rio de Janeiro. Thousands of attendees with leaders in international spine care were in attendance.

Their software team is leading a workshop and presenting a poster at this year’s SIGGRAPH Conference in Vancouver, the world’s premier graphics conference.

The cofounders, Eldrick and James, are giving the keynote at this year’s Stanford Mussallem Center for Biodesign Health Technology Showcase. Register here.

Top-tier seed funding: Recently closed a fresh round of funding, ranking in the top 1% of all seed-stage raises—a signal of investor confidence in the future of preventative aging diagnostics.

Achieved substantial commercial traction less than 10 months post-launch: Signed 125+ clinics worldwide since launching SystemAge, the first test to measure biological and organ-specific aging.

SystemAgeTM Test has demonstrated over 99.9% accuracy across tens of thousands of users.

Generated over 300 million data points on human aging, now fueling new insights into preventative care.

Recent breakthrough findings:

Featured in a recent Quanta Magazine interview with its co-inventor Manu Prakash, who reflects on the role of curiosity and observation in science. Developed as a low-cost tool for global health and education, Foldscope has been used to diagnose diseases like malaria in resource-limited settings. “Observation is a practice, and if you don’t practice, you lose it,” Prakash explains.

Actively raising a Seed round of capital to fund their goal of being the leading technology for multispecific antibody discovery. By quantitatively screening millions of antibodies for drug function, training AI models on huge quantitative data sets, and repeating, their platform has the potential to create the next generation of therapies for cancer, autoimmune disease, GPCR targets, and more—all in less than half the time of traditional discovery processes.

Will be at The Bullpen at the 2025 BIO International Convention in Boston 6/15 – 6/18 to discuss investment and partnership opportunities.

For more information, please reach out to [email protected]. They are seeking VCs, angels, and family offices to commit funds by end of July.